Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2009

01-05-2009 | Research Articles

Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays

Authors: Miquel Maciá i Garau, Josep Solé Monné, María José Cambra Serés, Carlota Monfà Binefa, Maribel Peraire Llopis

Published in: Clinical and Translational Oncology | Issue 5/2009

Login to get access
Metadata
Title
Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays
Authors
Miquel Maciá i Garau
Josep Solé Monné
María José Cambra Serés
Carlota Monfà Binefa
Maribel Peraire Llopis
Publication date
01-05-2009
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2009
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-009-0358-2

Other articles of this Issue 5/2009

Clinical and Translational Oncology 5/2009 Go to the issue

Brief Research Articles

Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution

Case Reports

Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer

News and Views

Perpetuum mobile

Educational Series

Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results

Case Reports

Gamma Knife radiosurgery as a primary treatment option for solitary brain metastases from ovarian carcinoma

Correspondence

Interstitial lung disease associated with oxaliplatin: description of two cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits